Arsenic trioxide (ATO) has shown substantial efficacy in the treatment of patients with acute promyelocytic leukemia, and the utilization of ATO as a potential treatment for other tumors is currently being investigated; thus, its clinical application is becoming more widespread. However, the toxicity of ATO has prevented many patients from receiving this highly beneficial treatment. The clinical features, mechanisms, and preventive measures for ATO hepatotoxicity, as well as potential curative strategies, are discussed in this review. This review not only discusses existing drugs for the treatment of hepatotoxicity but also focuses on potential future therapeutic agents, providing forward-looking guidance for the clinical use of small molecule extracts, trace elements, antidiabetic drugs, and vitamins.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882591 | PMC |
| http://dx.doi.org/10.3389/fphar.2025.1536388 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hepatotoxicity induced by arsenic trioxide: clinical features, mechanisms, preventive and potential therapeutic strategies.
Front Pharmacol
February 2025
Department of Haematology, Cancer Center, The First Hospital of Jilin University, Changchun, China.
Arsenic trioxide (ATO) has shown substantial efficacy in the treatment of patients with acute promyelocytic leukemia, and the utilization of ATO as a potential treatment for other tumors is currently being investigated; thus, its clinical application is becoming more widespread. However, the toxicity of ATO has prevented many patients from receiving this highly beneficial treatment. The clinical features, mechanisms, and preventive measures for ATO hepatotoxicity, as well as potential curative strategies, are discussed in this review.
View Article and Find Full Text PDFLncRNA MALAT1/Calpain-1 Axis in ATO Induced hERG Channel Deficiency.
Drug Des Devel Ther
March 2025
Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, People's Republic of China.
Background: KCNH2 encodes the hERG potassium channel, which is associated with drug-induced long QT syndrome. Arsenic trioxide (ATO) is an effective therapeutic agent for acute promyelocytic leukemia; however, its long-term use can lead to cardiotoxicity, particularly in cases of acquired long QT syndrome (acLQTS), which may result in torsade de pointes (TdP). Therefore, it is essential to comprehend the mechanisms behind acLQTS and to develop effective preventive and therapeutic strategies.
View Article and Find Full Text PDF[Acute promyelocytic leukemia with disseminated intravascular coagulation: a case report and literature review].
Zhonghua Xue Ye Xue Za Zhi
December 2024
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China.
Acute promyelocytic leukemia (APL) is characterized by an aggressive onset and rapid progression. During induction chemotherapy, it is prone to being complicated by disseminated intravascular coagulation (DIC), which is a leading cause of early death in patients. This study reports a case of APL complicated by DIC during induction therapy with all-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO).
View Article and Find Full Text PDFA pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia.
Blood Adv
February 2025
Johns Hopkins University, Baltimore, Maryland, United States.
SY-2101 is a novel oral formulation of arsenic trioxide (ATO). While intravenous (IV) ATO in combination with all trans retinoic acid is highly efficacious in the treatment of acute promyelocytic leukemia (APL) there remains a significant unmet need for patients due to the treatment burden associated with receiving daily ATO infusions over nearly a year of treatment and the risk of complications associated with indwelling central catheters. The pharmacokinetics (PK), safety, and tolerability of SY-‑2101 and ATO IV following single- and multiple-dose administration, and the impact of food on PK for SY-2101, were evaluated in this Phase 1 study in 15 participants with APL.
View Article and Find Full Text PDFPotential Common Molecular Mechanisms Between Periodontitis and Prostate Cancer: A Network Analysis of Differentially Expressed miRNAs.
In Vivo
February 2025
Department of Medical Biology, Kocaeli University Faculty of Medicine, Kocaeli, Turkiye.
Background/aim: Prostate cancer is the second leading cause of cancer-related deaths in men. Periodontitis is considered a high-risk factor for prostate cancer, but the genetic mechanism is unclear. This study aims to identify dysregulated miRNAs, their associated genes, signaling pathways, and compounds linking periodontitis to prostate cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!